Pharmaceutical and medical device companies are increasingly collecting gender identity data in clinical trials, patient support programs, and direct-to-patient marketing, aiming to increase representation and improve inclusion. However, mishandling this data can carry significant risks.
Under modern privacy frameworks, gender identity is treated as sensitive data, and improper collection, storage, or use can trigger regulatory fines, lawsuits, and reputational harm. For companies regulated by the Food and Drug Administration, these risks overlap with advertising, research integrity, and fraud/abuse oversight requirements.
The European Union’s General Data Protection Regulation applies to some activities originating within the United States, and US life sciences companies need to pay attention to how it may affect their handling of gender identity data. The GDPR explicitly protects “special categories” of personal data, including health, sexual orientation, and biometric data.
A growing number of US states have enacted privacy laws that may apply to gender identity data, such as the California Privacy Rights Act, which expanded the California Consumer Privacy Act to cover “sensitive personal information.” Consumers can limit the use of sensitive information to only what is “necessary” to deliver expected services.
Company policies for handling gender identity data should consider both privacy law risks and potential antidiscrimination law risks. Common pitfalls in the life sciences context include scope creep and reuse, where clinical trial sponsors initially collect gender identity for inclusion tracking but later reuse it for targeted marketing without consent.
Tokenism in clinical research can also lead to reputational and legal risk, where claiming that a clinical trial is inclusive of transgender people without conducting meaningful subgroup analysis or including related endpoints can create exposure for deceptive or discriminatory practices.
Related: Court Weighs Cell Phone Tracking Records
Regulatory penalties for mishandling gender identity data can be significant, with GDPR fines reaching up to 4 percent of global turnover and CCPA/CPRA enforcement fines reaching up to $7,500 per violation. Litigation exposure can also be substantial, with privacy claims increasingly bundled with discrimination and emotional distress allegations.
Reputational fallout from mishandling gender identity data can be severe.
By taking a proactive and thoughtful approach to handling gender identity data, life sciences companies can reduce the risk of regulatory penalties, litigation, and reputational harm, and build trust with patients, customers, and investors.
Regular audits and data protection impact assessments can help.
Establishing a privacy governance committee with oversight over gender identity data can ensure that these risks are properly managed, and companies can also review their policies for handling rape testing kits to ensure compliance with regulations.
Leave a Reply